Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis

[1]  S. Kische,et al.  Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN , 2020 .

[2]  A. Davenport,et al.  Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies , 2020, Journal of Nephrology.

[3]  S. Kische,et al.  Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  M. Fusaro,et al.  Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspective , 2020, Journal of Nephrology.

[5]  S. Bangalore,et al.  Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. , 2020, Journal of the American College of Cardiology.

[6]  A. Mügge,et al.  Risk stratification in patients undergoing interventional left atrial appendage occlusion—Prognostic impact of EuroSCORE II , 2020, Clinical cardiology.

[7]  M. Kelm,et al.  Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk , 2020, Acta cardiologica.

[8]  A. Regueiro,et al.  Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non-Valvular Atrial Fibrillation And End-Stage Renal Disease On Hemodialysis: A Single Center Experience. , 2019, Artificial organs.

[9]  A. Camm,et al.  EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  R. Akehurst,et al.  Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data , 2019, Journal of the American Heart Association.

[11]  P. Berne,et al.  Left Atrial Appendage Occlusion in High Bleeding Risk Patients , 2019, Journal of interventional cardiology.

[12]  J. MacRae,et al.  Anticoagulation in CKD and ESRD , 2019, Journal of Nephrology.

[13]  I. Cruz-González,et al.  Left Atrial Appendage Occlusion in Hemodialysis Patients: Initial Experience. , 2019, Revista espanola de cardiologia.

[14]  P. Berne,et al.  Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion , 2019, Journal of cardiovascular medicine.

[15]  P. Noseworthy,et al.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.

[16]  K. Chun,et al.  Antithrombotic strategies after interventional left atrial appendage closure: an update , 2018, Expert review of cardiovascular therapy.

[17]  J. Camm,et al.  Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  F. Pieruzzi,et al.  Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. , 2018, International journal of cardiology.

[19]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[20]  Jiangtao Yu,et al.  Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center , 2018, Heart and Vessels.

[21]  S. Kische,et al.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.

[22]  A. Santoro,et al.  Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study , 2017, Journal of Nephrology.

[23]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  Bingjian Wang,et al.  Efficacy and Safety of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Meta-analysis of Contemporary Studies. , 2016, Heart, lung & circulation.

[25]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  D. Brancaccio,et al.  Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.

[27]  P. Schulman,et al.  Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.

[28]  B. Meier,et al.  Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. , 2016, International journal of cardiology.

[29]  A. Santoro,et al.  Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[31]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[32]  G. Lip,et al.  Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[34]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[35]  C. Clase,et al.  Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[37]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.